Analgesic nephropathy and the renal concentrating mechanism.
D000375:Aging; D000686:Amyloidosis / Q000473:pathology; D000700:Analgesics / Q000009:adverse effects*; D000755:Anemia, Sickle Cell / Q000150:complications; D000818:Animals; D001241:Aspirin / Q000009:adverse effects; D002114:Calcinosis / Q000473:pathology; D003681:Dehydration / Q000150:complications; D048909:Diabetes Complications; D005260:Female; D006801:Humans; D007671:Kidney Concentrating Ability / Q000187:drug effects*; D007672:Kidney Cortex / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000139:chemically induced / Q000209:etiology*; D007679:Kidney Medulla / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D007681:Kidney Papillary Necrosis / Q000139:chemically induced* / Q000150:complications / Q000473:pathology; D008104:Liver Cirrhosis, Alcoholic / Q000150:complications; D008297:Male; D008954:Models, Biological; D009395:Nephritis, Interstitial / Q000209:etiology; D010615:Phenacetin / Q000009:adverse effects; D051381:Rats
D000700:Analgesics; D010615:Phenacetin; D001241:Aspirin